DressingScience & trialsAnimal healthCompanyNewsContact us

The science inside Premotiv®

Twenty years of nanoparticle research at Estonia’s National Institute of Chemical Physics and Biophysics, turned into a dressing that is now in one of the largest clinical trials in diabetic foot ulcers.

Electron micrograph of nanoparticles with a 200 nanometre scale bar

Particles you can only see under an electron microscope

Synergistic antibacterial nanoparticles are blended into natural silk nanofibres. The combination of copper and silver compounds is more effective together than either alone, which is the core of Premotiv® nanotechnology.

In laboratory tests of the veterinary version, the dressing was less toxic to human cells than other antibacterial dressings and showed the highest antibacterial activity against Staphylococcus aureus.

Natural silk nanofibres, wound contact layer
Copper nanoparticles
Silver nanoparticles

Infection control and wound closure

Non-antibacterial dressings support wound closure but do not prevent infection. Conventional antibacterial dressings prevent infection but can hold back closure.

Premotiv® is designed to sit in the sweet spot: preventing infection and promoting wound closure at the same time, across non-infected, unclear and severely infected wounds.

See the dressing and sizes

Diagram: Premotiv sits between non-antibacterial and antibacterial dressings, both preventing infection and promoting wound closure

The randomised controlled trial

Published in the Journal of Wound Care. The study concluded that the Premotiv® dressing is both safe and effective for treating diabetic foot ulcers.

ParameterDetail
SettingNorth Estonian Medical Centre (Põhja-Eesti Regionaalhaigla), Estonia’s largest hospital
Patients30 patients with diabetic foot ulcers, randomised into two groups
ComparatorSilver-ion (Ag+) wound dressing
TreatmentOne week, three dressing changes
Efficacy measuresWound area reduction, bacterial load, quality of life
Safety measuresAdverse events and blood levels
Wound area−43% with Nanordica vs −13% with silver-ion dressing
Bacterial loadStable with Nanordica, increased with silver-ion dressing

Now: 11 centres, 120+ patients

A multicentre, double-blind randomised trial in diabetic foot ulcers is under way in Estonia and Spain. It is designed to generate the evidence for reimbursement, treatment guidelines and broad clinical adoption.

“Antibacterial dressings supported by robust clinical evidence may influence future guideline recommendations and become category-defining solutions.”

Prof. Dr. José Luis Lázaro-Martínez, Chair of the EWMA Diabetic Foot Committee and principal investigator

Recently opened centres

  • Tartu University Hospital, Estonia
  • Hospital de Alcorcón, Madrid
  • Hospital Universitario Ramón y Cajal, Madrid
  • Universidad Complutense de Madrid
  • Clínica Universitaria de Podología, Universidad de León

Know a patient with a chronic diabetic foot ulcer in Estonia or Spain?

Refer a patient

Nanordica Medical team on stage at a wound care event

From the lab to the clinic

Nanordica Medical is a spin-off of the National Institute of Chemical Physics and Biophysics. Our quality management system is certified to ISO 13485:2016, and we are finalising CE marking for the European launch.

Clinical enquiries